The role of microRNA-9 in ovarian and cervical cancers: An updated overview

• Published in: European journal of surgical oncology p. 108546
• Main Authors: Di Fiore, Riccardo, Drago-Ferrante, Rosa, Suleiman, Sherif, Calleja, Neville, Calleja-Agius, Jean
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 18.07.2024
• Subjects: Biomarker; Cervical cancer; miR-9; Ovarian cancer; Therapeutics; miR-9; Biomarker; Cervical cancer; Therapeutics; Ovarian cancer
• ISSN: 0748-7983; 1532-2157; 1532-2157
• DOI: 10.1016/j.ejso.2024.108546

Ovarian and cervical cancers are the two most frequent kind of gynaecological cancers (GCs). In spite of advances in prevention, screening and treatment, cervical cancer still leads to an increased morbidity and mortality worldwide. Ovarian cancer is often detected at a late stage, which significantly reduces the effectiveness of available treatments. Therefore, novel methods are desperately needed to improve the clinical care of GC patients. MicroRNAs, also known as short noncoding RNAs (miRNAs/miRs), are a diverse group of RNAs with a length of 22 nucleotides. These typically cause translational repression and mRNA degradation by interacting with target mRNAs' 3′ untranslated region (3′-UTR), together with other regions and gene promoters. Under certain conditions, they are also able to activate translation or regulate transcription. It has been demonstrated that miRNAs are crucial to several biological processes leading to tumorigenesis, including GCs. Recent research has shown that miR-9 affects carcinogenesis. In this review, we will provide an overview of current research on the potential utility of miR-9 in the diagnosis, prognosis, and therapy of ovarian and cervical malignancies.